Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Exenatide LAR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A1 | PLACEBO_COMPARATOR | Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR |
| Group A2 | PLACEBO_COMPARATOR | Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR |
| Group B | EXPERIMENTAL | Exenatide lead-in followed by exenatide LAR 0.8 mg weekly |
| Group C | EXPERIMENTAL | Exenatide lead-in followed by exenatide LAR 2.0 mg weekly |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg |
| Exenatide LAR | DRUG | Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg. |
Inclusion Criteria: * Has type 2 diabetes treated with either: \*A stable regimen of metformin for a minimum of 3 months, and/or \*Diet modification and exercise for a minimum of 3 months. * Has HbA1c of 7.1% to 11.0%, inclusive. * Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive. Ex...
Exenatide LAR is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is a long-acting release formulation of exenatide, designed to provide sustained glucose control. As of the available data, it is in Phase 2 clinical development and has not been approved by regulatory authorities.
Exenatide LAR is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Type 2 Diabetes Mellitus.
Exenatide LAR is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 2 trial has been completed, and the drug is being studied for its potential use in treating Type 2 Diabetes Mellitus.
Exenatide LAR has one completed clinical trial registered under NCT00103935, titled 'Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes'. This Phase 2, randomized, double-blind, placebo-controlled study enrolled 45 participants in the United States. The trial has been completed, and no active trials are currently listed.
Exenatide LAR is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus. The completed Phase 2 trial (NCT00103935) evaluated its safety and efficacy, but the drug has not yet received regulatory approval from the FDA or any other health authority.